Company profile: Applied Genetic Technologies
1.1 - Company Overview
Company description
- Provider of AAV-based gene therapies, conducting human clinical trials for rare diseases. Offerings include AGTC-501, a Phase 2/3 gene therapy for X-Linked Retinitis Pigmentosa delivering full-length RPGR, preclinical AAV programs for dry age-related macular degeneration and cone rod dystrophy, and the VISTA Phase 2/3 trial evaluating AGTC-501.
Products and services
- AGTC-501: A Phase 2/3 clinical-stage gene therapy that delivers a full-length RPGR protein to address genetic causes of X-Linked Retinitis Pigmentosa
- VISTA Trial: A Phase 2/3 clinical trial evaluating the efficacy and safety of AGTC-501 for X-Linked Retinitis Pigmentosa
- AAV Gene Therapy: An AAV-based platform that uses vectors to deliver therapeutic genes for retinal disorders, modifying patient cells to produce necessary proteins
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Applied Genetic Technologies
BioMarin
HQ: United States
Website
- Description: Provider of innovative biopharmaceuticals for serious diseases and medical conditions, developing and commercializing them.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMarin company profile →
Soleno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies, developing DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral treatment in development for Prader-Willi syndrome (PWS) and other rare endocrine disorders, designed to reduce hyperphagia, improve behavior, and manage metabolic health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Soleno Therapeutics company profile →
Pharming
HQ: The Netherlands
Website
- Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharming company profile →
Mitobridge
HQ: United States
Website
- Description: Provider of small molecule therapeutics that improve mitochondrial function to address diseases with high unmet need. Pipeline includes investigational candidates: ASP0367 for primary mitochondrial myopathies and Duchenne muscular dystrophy, ASP1128 for acute kidney injury, and an NAD+ modulation program targeting aging-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitobridge company profile →
Aeovian Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for rare and age-related diseases, focused on discovering, developing, and commercializing treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeovian Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Applied Genetic Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Applied Genetic Technologies
2.2 - Growth funds investing in similar companies to Applied Genetic Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Applied Genetic Technologies
4.2 - Public trading comparable groups for Applied Genetic Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →